“Valve-in-valve” transcatheter aortic valve implantation (ViV-TAVI) is an alternative to conventional redo surgery for bioprosthetic aortic valve replacement (AVR) dysfunction1 but ViV-TAVI for degenerate stentless bioprostheses is challenging2. We report the five-year follow-up of a single-centre consecutive series of patients undergoing ViV-TAVI for degenerate homograft AVR.
All patients receiving ViV-TAVI for degenerate homograft AVR between October 2009 and April 2019 were retrospectively analysed. Clinical, echo, and brain natriuretic peptide (BNP) levels were measured preprocedurally and after 1, 3, and 5 years. The Royal Brompton and Harefield Clinical Practice Committee approved the study protocol, the study was performed ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com